Retrospective observational study evaluating the clinical utility of liquid biopsy in cancer genomic profiling for patients with non-small cell lung cancer: impact on treatment recommendation rates, treatment initiation rates, and patient characteristics.

Retrospective observational study evaluating the clinical utility of liquid biopsy in cancer genomic profiling for patients with non-small cell lung cancer: impact on treatment recommendation rates, treatment initiation rates, and patient characteristics. - Real-world utility of liquid biopsy in NSCLC CGP

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060867

Enrollment

Registered

2026-05-10

Start date

2026-05-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with non-small cell lung cancer aged 20 years or older at the time of testing, who underwent liquid biopsy-based cancer genomic profiling at Tohoku University Hospital between January 2019 and March 2026.

Exclusion criteria

Exclusion criteria: Patients judged inappropriate for the study by the principal or sub-investigator at each institution (e.g., due to a lack of essential clinical data required for analysis). Patients who declined to participate in the study through the opt-out process.

Design outcomes

Primary

Measure	Time frame
Treatment recommendation rate	—

Secondary

Measure	Time frame
Treatment delivery rate, Genomic alteration detection rate, number of detected variants, ctDNA non-detection rate, overall survival stratified by the presence or absence of treatment recommendations based on liquid CGP, analysis of reasons for treatment non-delivery in patients who received treatment recommendations, and patient background factors immediately prior to liquid CGP for patients with treatment recommendations (treatment line, PS, maximum tumor diameter, number of metastatic sites, presence or absence of liver and brain metastases, LDH, CRP, NLR, WBC, and neutrophil count)	—

Measure

Time frame

Treatment delivery rate, Genomic alteration detection rate, number of detected variants, ctDNA non-detection rate, overall survival stratified by the presence or absence of treatment recommendations based on liquid CGP, analysis of reasons for treatment non-delivery in patients who received treatment recommendations, and patient background factors immediately prior to liquid CGP for patients with treatment recommendations (treatment line, PS, maximum tumor diameter, number of metastatic sites, presence or absence of liver and brain metastases, LDH, CRP, NLR, WBC, and neutrophil count)

—

Countries

Japan

Contacts

Public ContactChikashi Iwasaki

Tohoku University Hospital Department of Respiratory Medicine

chikashi.iwasaki.e3@tohoku.ac.jp022-717-8539

Outcome results